Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of Phase II Trial

被引：4
|
作者：
William, Basem M. [1 ]
Huang, Ying [1 ]
Johnson, Amy [2 ]
Brammer, Jonathan E. [3 ]
Reneau, John C. [2 ]
Maakaron, Joseph [2 ]
Larbi, Ruth [2 ]
Grantier, Cara [2 ]
Hoffman, Corinne [2 ]
Ayyappan, Sabarish [3 ]
Baiocchi, Robert A. [2 ]
Epperla, Narendranath [2 ]
Christian, Beth A. [1 ]
Alinari, Lapo [2 ]
Maddocks, Kami J. [2 ]
Chung, Catherine [2 ]
机构：
[1] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA
[2] Ohio State Univ, Ctr Comprehens Canc, Arthur G James Canc Hosp & Richard J Solove Res I, Div Hematol, Columbus, OH 43210 USA
[3] Ohio State Univ, James Comprehens Canc Ctr, Columbus, OH 43210 USA
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-123801
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2853
引用
收藏
页数：3
相关论文
共 50 条
  • [1] A phase II trial of brentuximab vedotin (BV) and lenalidomide (Len) in relapsed and refractory (r/r) cutaneous (CTCL) and peripheral (PTCL) T-cell lymphomas
    Maakaron, J.
    Huang, Y.
    Brammer, J.
    Chung, C.
    William, B.
    EUROPEAN JOURNAL OF CANCER, 2019, 119 : S28 - S28
  • [2] A Phase II Trial of Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; Preliminary Results
    William, Basem
    Huang, Ying
    Brammer, Jonathan
    Chung, Catherine
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S359 - S360
  • [3] Nivolumab plus brentuximab vedotin for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma
    Zinzani, Pier Luigi
    Salles, Gilles
    Moskowitz, Alison J.
    Santoro, Armando
    Mehta, Amitkumar
    Barr, Paul M.
    Mehta-Shah, Neha
    Collins, Graham P.
    Ansell, Stephen M.
    Brody, Joshua D.
    Domingo-Domenech, Eva
    Johnson, Nathalie A.
    Cunningham, David
    Ferrari, Silvia
    Lisano, Julie
    Krajewski, Jennifer
    Wen, Rachael
    Akyol, Alev
    Crowe, Russell
    Savage, Kerry J.
    BLOOD ADVANCES, 2024, 8 (10) : 2400 - 2404
  • [4] Phase II Trial Of Brentuximab Vedotin For CD30+Cutaneous T-Cell Lymphomas and Lymphoproliferative Disorders
    Duvic, Madeleine
    Tetzlaff, Michael
    Clos, Audra L.
    Gangar, Pamela
    Talpur, Rakhshandra
    BLOOD, 2013, 122 (21)
  • [5] Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphomas and Lymphoproliferative Disorders
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2014, 12 (02) : 10 - 11
  • [6] Brentuximab Vedotin (BV) in Combination With Lenalidomide (Len) and Rituximab (R) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Results From the Phase 3 ECHELON-3 Study
    Yasenchak, Christopher
    Kim, Jeong-A
    Hahn, Uwe
    Kim, Won-Seog
    Fleury, Isabelle
    Laribi, Kamel
    Bergua Burgues, Juan Miguel
    Bouabdallah, Krimo
    Forward, Nicholas
    Bijou, Fontanet
    MacDonald, David
    Portell, Craig
    Ghesquieres, Herve
    Nowakowski, Grzegorz
    Rustia, Evelyn
    Fanale, Michelle
    Jie, Fei
    Bartlett, Nancy
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S490 - S491
  • [7] Complete responses (CR/CRu) on a phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL)
    Horwitz, S. M.
    Coiffier, B.
    Foss, F. M.
    Prince, H. M.
    Sokol, L.
    Greenwood, M.
    Caballero, D.
    Borchmann, P.
    Morschhauser, F.
    Wilhelm, M.
    Pinter-Brown, L. C.
    Padmanabhan, S.
    Shustov, A. R.
    Nichols, J.
    Balser, J.
    Carroll, S.
    Pro, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [8] Phase II Study of Lenalidomide Maintenance after Salvage Therapy for Relapsed or Refractory Peripheral T-Cell Lymphomas
    Kim, Seok Jin
    Lee, Myung-Won
    Lim, Sung-Nam
    Kang, Ka-Won
    Yoon, Sang Eun
    Lee, Yoo Jin
    Kang, Hye Jin
    Lee, Ho Sup
    Kim, Hyo Jung
    Koo, Hong Hoe
    Shin, Ho-Jin
    Eom, Hyeon-Seok
    Won, Jong-Ho
    Kim, Won Seog
    BLOOD, 2023, 142
  • [9] Brentuximab vedotin in refractory or relapsed peripheral T-cell lymphomas: the French named patient program experience in 56 patients
    Lamarque, Mathilde
    Bossard, Celine
    Contejean, Adrien
    Brice, Pauline
    Parrens, Marie
    Le Gouill, Steven
    Briere, Josette
    Bouabdallah, Reda
    Canioni, Danielle
    Tilly, Herve
    Bouchindhomme, Brigitte
    Bachy, Emmanuel
    Delarue, Richard
    Haioun, Corinne
    Gaulard, Philippe
    HAEMATOLOGICA, 2016, 101 (03) : E103 - E106
  • [10] Phase II trial of oral suberoylanilide hydroxamic acid (SAHA) for cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL).
    Duvic, M
    Talpur, R
    Chiao, N
    Chiao, J
    BLOOD, 2003, 102 (11) : 179A - 180A
12345